U.S. flag An official website of the United States government
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. National Center for Toxicological Research
  7. Science & Research (NCTR)
  8. NCTR Research Offices and Divisions
  9. NCTR Division of Genetic and Molecular Toxicology
  1. NCTR Research Offices and Divisions

NCTR Division of Genetic and Molecular Toxicology Also referred to as: DGMT

About the Division


Improve public health by providing FDA with the expertise, tools, and approaches necessary for the comprehensive assessment of genetic risk.

2022 Select DGMT Accomplishments

Close-up image of microscope

Guidelines for Conducting Rodent Erythrocyte Pig-a Assay

DGMT scientists led a multinational consortium in drafting a Test Guideline (TG) for conducting the rodent erythrocyte Pig-a gene mutation assay. The assay is used by the FDA to evaluate the carcinogenic hazards of regulated substances. DGMT provided recommendations in 2021, which cleared the way for the TG to be published in June 2022 by the Organization for Economic Co-operation and Development. This guideline will ensure that data submitted for regulatory safety assessments of most FDA-regulated products are of uniformly high quality.

Mutation Analysis Using Error-Corrected Next Generation Sequencing

Error-corrected Next Generation Sequencing (ec-NGS) is a potentially powerful approach for evaluating rare mutations directly by the changes they make in the DNA sequence of the genome. Mutation is used by the FDA in safety evaluations of regulated products as a biomarker of carcinogenicity. DGMT scientists successfully conducted ec-NGS analyses in bacteria, C. elegans, and mammalian cells, including the cells from an organotypic tissue model, using two platforms — Duplex Sequencing and PacBio HiFi Sequencing.

DGMT scientists are frequently asked to consult in evaluating genetic toxicology data and have hands-on expertise in conducting common regulatory genetic toxicology assays (e.g., Ames, TGR, Comet and Pig-a).

Ongoing DGMT Research Projects in 2023

  • Evaluate high-content high-throughput genetic toxicology using metabolically active hepatic cell lines and primary hepatic cells from humans
  • Analyze genetic toxicology using a panel of 14 human cell lines, each expressing a different human drug metabolizing enzyme
  • Evaluate mutagenicity of drug impurities in support of the Center for Drug Evaluation and Research Nitrosamine Drug Impurity Task Force 
  • Validate study of vitrocell exposure systems to investigate the in vitro toxicity of electronic nicotine delivery systems at the air-liquid interface of human airway tissue models
  • Develop an in vitro system to evaluate the disease-related toxic effects of inhaled aerosols and vapors in human airway tissue models
  • Develop an in vitro co-culture system to test the adverse effects of drugs and their metabolites on human embryo-fetal development
  • Develop a microphysiological system for evaluating Zika Virus sexual transmission using a testicular model
  • Develop a microphysiological system for evaluating antibody therapies targeting viral infections during pregnancy: a Zika Virus case study

Resources For You

Contact Us

Contact Point
National Center for Toxicological Research
Food and Drug Administration
3900 NCTR Rd
Jefferson, AR 72079
Hours Available
(870) 543-7121

Subscribe to NCTR Research Highlights Newsletter

Get regular FDA email updates delivered on this topic to your inbox.

Back to Top